Wednesday, April 27, 2022 6:04:21 AM
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence (AI) approaches to identify and develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its first quarter 2022 financial results on Monday, May 9, 2022 before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and webcast at 8:30 AM ET to discuss the Company’s financial results and to provide a general business update.
Conference Call & Webcast Details
Date/Time:
Domestic:
International:
Monday, May 9, 2022 at 8:30 AM Eastern Time
877-407-5795
201-689-8722
The webcast and the accompanying materials will be accessible* under "News/Events" on the Investors & Media page of the Company's website at www.bioxceltherapeutics.com.
Recent BTAI News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 08:05:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 11:00:27 AM
- BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation • GlobeNewswire Inc. • 09/19/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 11:23:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 11:21:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 11:20:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 11:18:35 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 09/17/2024 11:17:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/16/2024 09:42:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/16/2024 09:26:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/16/2024 09:16:32 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/16/2024 05:23:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:15:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 11:16:38 AM
- BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia • GlobeNewswire Inc. • 09/05/2024 11:00:00 AM
- BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 01:05:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 11:05:19 AM
- BioXcel Therapeutics Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/06/2024 11:00:00 AM
- BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024 • GlobeNewswire Inc. • 07/30/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 08:41:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 11:00:27 AM
- BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film • GlobeNewswire Inc. • 07/16/2024 11:00:00 AM
- BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia • GlobeNewswire Inc. • 06/25/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/19/2024 01:27:09 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM